Eisai secures Japanese Aricept patent extension for severe Alzheimer's
This article was originally published in Scrip
The Japanese patent relating to the use of Eisai's Aricept (donepezil) for the severe form of Alzheimer's disease has been extended to 22 June 2013, handing the company a victory in a long-running legal battle with potential generic competitors in this setting.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.